Scientific Advancements: Center News
Barry Singer, MD, our center’s director, continues to work hard to further our understanding of multiple sclerosis and advance treatment. He presented scientific posters at the Academy of Neurology Meeting in Vancouver in April 2016. Topics were the efficacy of using Lemtrada (alemtuzumab) in patients with highly active multiple sclerosis and rapid benefits of Gilenya (fingolimod) in relapsing forms of multiple sclerosis.
Dr. Singer also just published a chapter in Seminars in Neurology on FDA-approved and future monoclonal antibody treatments for multiple sclerosis. Tysabri (natalizumab) and Lemtrada (alemtuzumab) are currently available. Hopefully, both Ocrevus (ocrelizumab) and Zinbryta (daclizumab) will be available within the year. His chapter also covers remyelination antibodies being studied in clinical trials including opicinumab (Anti-LINGO-1) and rHIgM22.
In addition, Dr. Singer was extremely pleased to join the Board of Directors for the Multiple Sclerosis Association of America. As a global patient advocate, this position will allow him to further press for options for those living with multiple sclerosis.
BY: Barry Singer, MD DATE: May 14, 2016 TOPIC: MS Center News